SPDR S&P Biotech ETF (NYSEArca: XBI)
2012: 32.4%
2013: Up 39.6%
Comment: XBI is the equal-weight fund in the biotech ETF group, so that means substantially lower allocations to biotech’s Big Four and more exposure to less familiar names. It appears unlikely that XBI will be on the 2013 Top-10 Sector ETF list, but it is hard to complain when the fund has been this year than it was last year.